Biograil is a Copenhagen-based biotech developing pharmaceutical products around its proprietary BIONDD device: an injection-molded, bio-compostable capsule that delivers therapeutics, including biologics that normally require injection, into the stomach mucosal wall for systemic distribution. Founded in 2019 by seasoned entrepreneurs and R&D executives behind the first FDA-approved injection-molded oral tablet, the company is preparing BIONDD for Phase 1 clinical testing, backed by investors including Verve Ventures, Megatrend Invest, High-Tech Gründerfonds, Eli Lilly and Co., Evonik Venture Capital and Roquette Ventures.
1
Round
1
Industry
5
Tags
Nov 4, 2026
Latest raise
Funding activity · 1 round
Nov 4, 2026
EUR 20M
Undisclosed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
